We are live on ! Find out more
ZBIO

Zenas BioPharma
ZBIO

44 hedge funds and large institutions have $419M invested in Zenas BioPharma in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

62.25% more ownership

Funds ownership: 0% → 62.25% (+62%)

Holders
44
Holders Change
+44
Holders Change %
–
% of All Funds
0.63%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.06%
New
44
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SOCM
SR One Capital Management
Pennsylvania
+$88.3M
2
NMC
NEA Management Company
Maryland
+$47M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$36M
4
FFM
Fairmount Funds Management
Pennsylvania
+$34M
5
NA
NVP Associates
California
+$33.1M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
SOCM
1
SR One Capital Management
Pennsylvania
$83.1M +$88.3M +4,911,539 New
NMC
2
NEA Management Company
Maryland
$44.2M +$47M +2,613,948 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$33.8M +$36M +2,000,000 New
FFM
4
Fairmount Funds Management
Pennsylvania
$32M +$34M +1,892,806 New
NA
5
NVP Associates
California
$31.1M +$33.1M +1,838,482 New
DM
6
Deerfield Management
New York
$26.4M +$28.1M +1,562,942 New
Wellington Management Group
7
Wellington Management Group
Massachusetts
$24.8M +$27M +1,501,428 New
VC
8
Vivo Capital
California
$20M +$21.3M +1,183,260 New
Federated Hermes
9
Federated Hermes
Pennsylvania
$19.6M +$20.8M +1,158,000 New
NHAS
10
Novo Holdings A/S
Denmark
$19.5M +$20.7M +1,150,000 New
PA
11
Perceptive Advisors
New York
$19.4M +$20.6M +1,144,035 New
RSCM
12
Rock Springs Capital Management
Maryland
$14.9M +$15.8M +878,667 New
PBPIA
13
Pivotal bioVenture Partners Investment Advisor
California
$11M +$11.7M +650,695 New
T. Rowe Price Associates
14
T. Rowe Price Associates
Maryland
$8.24M +$8.75M +486,854 New
ACH
15
ArrowMark Colorado Holdings
Colorado
$5.08M +$5.39M +300,000 New
EP
16
Eversept Partners
New York
$3.22M +$3.43M +190,531 New
MIM
17
Monashee Investment Management
Massachusetts
$2.54M +$2.7M +150,000 New
Vanguard Group
18
Vanguard Group
Pennsylvania
$2.54M +$2.7M +150,000 New
Goldman Sachs
19
Goldman Sachs
New York
$2.24M +$2.38M +132,400 New
Millennium Management
20
Millennium Management
New York
$1.99M +$2.11M +117,381 New
SCM
21
Superstring Capital Management
New York
$1.89M +$2.01M +111,605 New
Citadel Advisors
22
Citadel Advisors
Florida
$1.6M +$1.7M +94,322 New
Aberdeen Group
23
Aberdeen Group
United Kingdom
$1.27M +$1.35M +75,100 New
Norges Bank
24
Norges Bank
Norway
$1.27M +$1.35M +75,000 New
Point72 Asset Management
25
Point72 Asset Management
Connecticut
$975K +$1.04M +57,600 New
1
2

ZBIO Hedge Fund Activity: Q3 2024 in Review

44 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Zenas BioPharma (ZBIO) for Q3 2024, worth a combined $419M.

Buyers outnumbered sellers: 44 funds opened new ZBIO positions and 0 closed out — a net gain of 44 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was SR One Capital Management, opening a new position worth an estimated $88.3M.

  • 44 institutional investors held Zenas BioPharma (ZBIO) as of Q3 2024, up from 0 in Q2 2024.
  • Funds reported $419M of Zenas BioPharma stock for Q3 2024.
  • 44 funds opened new Zenas BioPharma positions in Q3 2024 and 0 closed out, a net change of +44 holders.
  • The largest Zenas BioPharma buyer in Q3 2024 was SR One Capital Management, an estimated $88.3M added.

Based on aggregated 13F filings for Q3 2024.